New York, December 21, 2023 – In two weeks, 2023 will be history so consider this your reminder to start figuring out a resolution that
New York, December 21, 2023 – Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company’s innovative StemSpine® treatment
New York, December 21, 2023 – Palatin Technologies, Inc. (NYSE American: PTN) has completed the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, specialty pharmaceutical company, for up to
New York, December 20, 2023 – Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella
New York, December 19, 2023 – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of
NEW YORK, NY, December 18, 2023 – Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized
NEW YORK, NY, December 18, 2023 – Shares in Battalion Oil Corporation (NYSE American: BATL) surged more than 80% on Friday after the company announced it has agreed
In the fast-paced landscape of experiential design and technology, Creative Realities Inc. seamlessly integrates the physical and digital realms in creating immersive experiences that captivate
NEW YORK, NY, December 15, 2023 – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate
NEW YORK, NY, December 14, 2023 – In the fast-paced landscape of experiential design and technology, Creative Realities Inc. ($CREX) seamlessly integrates the physical and
PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850
